Please upgrade your browser.
Ulka Vaishampayan, MD writes: Biomarkers represent the future of renal cancer therapeutics. With six new targeted-therapy agents receiving U.S. Food and Drug Administration approvals, and many more maturing toward becoming established therapies, optimization of these treatments has become a dire need of the moment. Current prognostic information is predominantly reliant on patient and tumor characteristics and is derived from basic clinical history, physical examination, and laboratory tests.
The well-informed kidney cancer patient is the empowered patient, but is it wise to rely on the interpretation of medical information by other lay people? Perhaps not. In this podcast we discuss the importance of doing your own fact-finding.
This page is dedicated to bringing you the most current information about clinical trials for papillary kidney cancer. In a small number of cases, papillary renal cell carcinoma is hereditary. This disease accounts for a small percentage of all cases of kidney cancer.
2012 Genitourinary Cancers Symposium Daily News: By: Sima Porten, MD, MPH, and Maxwell V. Meng, MD The past decade has seen significant advances in the treatment of patients with renal cell carcinoma, with the widespread adoption of minimally invasive surgical techniques and the approval of several targeted systemic agents for metastatic disease.
By: Thomas Powles, MD The introduction of agents targeting angiogenesis and the mTOR pathway have substantially improved the outcome of metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy remains the standard of care in the era of targeted therapy. This is based on data from two randomized trials comparing nephrectomy and immune therapy with immune therapy alone.
AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival
Kidney clear cell carcinoma is the most common type of kidney cancer, representing approximately 92 percent of such cases. Papillary carcinoma accounts for about 8 percent.
The Kidney Cancer Association is podcasting live from the 2012 Genitourinary Cancers Symposium, in San Francisco. For the latest information from this event,be sure to read the "Daily News" online.
The data indicate that dendritic cells (DCs) vaccination, which is a personalised treatment modality, maintains quality of life (QoL) and thus represents an attractive nontoxic treatment option for patients with metastatic renal cell carcinoma (RCC).
To evaluate characteristic imaging findings of tumor attenuation in multiphase computed tomography (CT) between renal oncocytomas and clear-cell renal cell carcinoma (ccRCC) of small tumor size (=5cm).
|Powered by NeonCRM|